The Evolution of Thrombolytic Therapy and Adjunctive Antithrombotic Regimens in Acute ST-Segment Elevation Myocardial Infarction

American Journal of Emergency Medicine

Volumn 22, Issue 1, 2004, Pages 14-23

  Cohen, Marc ^a   Arjomand, Heidar ^b   Pollack Jr , Charles V ^c  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Acute myocardial infarction; Adjunctive therapy; Fibrinolysis; Reperfusion

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; RETEPLASE; STREPTOKINASE; TENECTEPLASE;

ACUTE HEART INFARCTION; ANAPHYLACTIC SHOCK; ARTERY OCCLUSION; BLEEDING; BLOOD CLOTTING; BRADYCARDIA; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SELECTIVITY; EMERGENCY HEALTH SERVICE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART REINFARCTION; HUMAN; HYPOTENSION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RASH; REVIEW; SHIVERING; ST SEGMENT ELEVATION; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0742323181     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2003.09.001     Document Type: Article

References (51)

1. Ryan T, Antman EM, Brooks NH, et al: 1999 updateACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction): J Am Coll Cardiol 1999;34:890-911
2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360
4. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators: Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-722
5. Topol EJ: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-1914
6. Ross AM, Molhoek P, Lundergan C, et al: Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-652
7. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613
8. The GUSTO investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682
9. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622
10. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators: A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337: 1118-1123
11. Bell WR Jr: Evaluation of thrombolytic agents. Drugs 1997; 54:11-16; discussion 16-17
12. Llevadot J, Giugliano RP, Antman EM: Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 2001;286:442-449
13. Stewart RJ, Fredenburgh JC, Leslie BA, et al: Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J Biol Chem 2000;275:10112-10120
14. Walls RM, Pollack CV: Successful cricothyrotomy after thrombolytic therapy for acute myocardial infarction: a report of two cases. Ann Emerg Med 2000;35:188-191
15. Davydov L, Cheng JW: Tenecteplase: a review. Clin Ther 2001;23:982-997; discussion 981
16. Cannon CP, McCabe CH, Gibson CM, et al: TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351-356
17. Cannon CP, Gibson CM, McCabe CH, et al: TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98:2805-2814
18. Fitzgerald DJ, Catella F, Roy L, et al: Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-150
19. Topol EJ: Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998;97:211-218
20. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782
21. Antman EM: Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 1996;94:911-921
22. White H: Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358:1855-1863
23. Verstraete M: Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990;40:498-530
24. Kontny F, Dale J, Abildgaard U, et al: Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997;30:962-969
25. Frostfeldt G, Ahlberg G, Gustafsson G, et al: Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction-a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999; 33:627-633
26. Wallentin L, Dellborg DM, Lindahl B, et al: The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study. Clin Cardiol 2001;24:112-114
27. Cohen M, Demers C, Gurfinkel EP, et al: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452
28. Antman EM, McCabe CH, Gurfinkel EP, et al: Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601
29. Antman EM, Cohen M, Radley D, et al: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11 B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608
30. Cohen M: Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction. Semin Thromb Hemost 1999;25:113-121
31. Cohen M, Antman EM, Gurfinkel E, et al: Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction. Am J Cardiol 2000;86:553-556, 9A
32. Glick A, Kornowski R, Michowich Y, et al: Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996;77:1145-1148
33. Simoons ML, Krzemiñska-Pakula M, Alonso A, et al: Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 2002;23:1282-1290
34. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology: Acute myocardial infarction: pre-hospital and in-hospital management. Eur Heart J 1996;17:43-63
35. Antman EM, Louwerenburg HW, Baars HF, et al: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-1649
36. Coussement PK, Bassand JP, Convens C, et al: A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001;22:1716-1724
37. Foster RH, Wiseman LR: Abciximab. An updated review of its use in ischaemic heart disease. Drugs 1998;56:629-665
38. McClellan KJ, Goa KL: Tirofiban: a review of its use in acute coronary syndromes. Drugs 1998;56:1067-1080
39. Goa KL, Noble S: Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 1999;57:439-462
40. Ohman EM, Kleiman NS, Gacioch GCombined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators: Circulation 1997;95:846-854
41. Antman EM, Giugliano RP, Gibson CM, et al: Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999;99:2720-2732
42. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group: Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000; 101:2788-2794
43. Richards CF, Cannon CP: Reducing medication errors: potential benefits of bolus thrombolytic agents. Acad Emerg Med 2000;7:1285-1289
44. Wallentin L, Goldstein P, Armstrong PW, et al: Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin of unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135-142
45. Aversano T, Aversano LT, Passamani E, et al: Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: A randomized controlled trial. JAMA 2002;287: 1943-1951
46. Anderson HR: The Danish Multicenter Randomized Trial on Thrombolytic therapy vs Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2). Presented at the Late Breaking Clinical Trials Session III, 51st Annual Scientific Session of the American College of Cardiology; Atlanta, Georgia; March 2002
47. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20
48. PCAT Collaborators: Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow-up and analysis of individual patient data from randomized trials. Am Heart J 2003;145:47-57
49. Montalescot G, Barragan P, Wittenberg O, et al: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903
50. Stone GW, Grines CL, Cox DA, et al: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966
51. Ross AM, Coyne KS, Reiner JS, et al: A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999;34:1954-1962